IL1R1
ENSG00000115594
Target class
Membrane receptor
Chromosome
2
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- IL1R1
- Gene name
- Interleukin 1 receptor type 1
- Gene symbol
- IL1R1
- Protein name
- Interleukin-1 receptor type 1 (IL-1R-1) (IL-1RT-1) (IL-1RT1) (EC 3.2.2.6) (CD121 antigen-like family member A) (Interleukin-1 receptor alpha) (IL-1R-alpha) (Interleukin-1 receptor type I) (p80) (CD antigen CD121a) [Cleaved into: Interleukin-1 receptor type 1, membrane form (mIL-1R1) (mIL-1RI); Interleukin-1 receptor type 1, soluble form (sIL-1R1) (sIL-1RI)]
- D2S1473
- CD121A
- IL1R
- IL1RA
- Gene biotype
- Protein coding
- Gene family
- CD molecules|I-set domain containing|Interleukin receptors|TIR domain containing
- Target class
- Membrane receptor
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 188.51
- Tissue specificity (Gini)
- 0.521
- Tissue specificity (tau)
- 0.817
- KEGG gene identifiers
- hsa:3554
- Protein interaction confidence
- 0.839266
- Protein interaction partners
- 64
- R-HSA-6783783
- R-HSA-9020702
- R-HSA-9679191
- End position
- 102179874
- Start position
- 102063933
- Chromosome
- 2
- Strand
- Forward
- Membrane
- Single-pass type I membrane protein . Cell membrane . Secreted .
- Cytosol
- Nucleoplasm
- Plasma membrane
- Vesicles
Publication evidence
- PubMed 8142597
- Tissue specificity (tau)
- 0.816701
- Expression inequality (Gini)
- 0.520578
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 188.51
- Lung
- 141.39
- Adipose - Visceral (Omentum)
- 140.12
- Adipose - Subcutaneous
- 112.56
- Breast - Mammary Tissue
- 82.34
Expression in transcripts per million
- Cells - Cultured fibroblasts188.51
- Lung141.39
- Adipose - Visceral (Omentum)140.12
- Adipose - Subcutaneous112.56
- Breast - Mammary Tissue82.34
- Prostate76.58
- Thyroid74.71
- Cervix - Endocervix67.33
- Fallopian Tube63.82
- Artery - Coronary63.36
- Adrenal Gland59.01
- Artery - Aorta58.04
- Bladder54.89
- Cervix - Ectocervix53.46
- Vagina51.05
- Skin - Sun Exposed (Lower leg)42.54
- Esophagus - Gastroesophageal Junction42.17
- Spleen42.16
- Skin - Not Sun Exposed (Suprapubic)41.39
- Artery - Tibial39.5
- Small Intestine - Terminal Ileum38.47
- Uterus37.75
- Esophagus - Muscularis36.87
- Minor Salivary Gland36.44
- Colon - Sigmoid32.48
And 29 more, listed on the interactive page.
- GO:0006955
- GO:0007166
- GO:0010641
- GO:0032729
- GO:0043123
- GO:0051897
- GO:0070498
- GO:0070555
- GO:2000556
- GO:0005886
- GO:0016020
- GO:0004888
- GO:0004908
- GO:0004909
- GO:0005161
- GO:0005515
Related records
Trials (285)
- "IL-1β Blockade to Prevent Immunothrombosis in Recipients of a Pancreatic Organ"
- 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia
- A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease
- A Dose-Block Randomized, Placebo Controlled (Double-blind), Active Controlled(Open-label), Dose-escalation Study
- A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
- A Multiple Dose Study to Evaluate Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis
- A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
- A Pilot Study to Assess the Immunogenicity and Reactogenicity of High Versus Standard Dose TIV
- A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic Dermatitis
- A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy
- A Randomized Double Blind, Placebo Controlled Trial With AMG 108 in Patients With Type 2 Diabetes Mellitus
- A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People With RA & Receiving Methotrexate
- A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S
- A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML
- A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study
- A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)
- A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
- A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer
- A Study of CellCept (Mycophenolate Mofetil) Combined With Tacrolimus and Corticosteroids in Kidney Transplant Patients.
- A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Liver Transplant Patients.
Drugs (3)
- AMG-108 Interleukin-1 receptor antagonist
- Anakinra Interleukin-1 receptor antagonist
- MEDI-8968 Interleukin-1 receptor inhibitor